Mice Model Generation Market (Technology: CRISPR Knockout, CRISPR Knockin, Random Insertions, Large & Targeted Insertions, ES Cell Modification, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Mice Model Generation market size is expected to hit around USD 1.4 billion by 2030 from valued at USD 524.6 Million in 2021 and growing at a CAGR of 8.32% from 2022 to 2030.

Mice are efficient and cost-effective research tools. Mice model inception began in the early 1900s on a farm in Granby, Massachusetts. Mice models are more advantageous than other animal models, as 99% of their genome is similar to the human genome. Rise in prevalence of cancer, cardiovascular diseases, diabetes, autism, schizophrenia, and rare diseases; increase in the burden of obesity; and growth of genetic disorders are propelling the global mice model generation market. Emergence of CRISPR as a powerful tool in the field of biomedical research and surge in applications of CRISPR technology in several industry segments are augmenting the global mice model market.

Report Scope of the Mice Model Generation Market

Personalized In Vivo Analysis of Mice Models to Propel Global Mice Model Generation Market

Advancement in gene technology, fueled by the need for fast and accurate treatment, in the ever-evolving medical industry is driving the mice model market. Identification of genomic differences to predict drug resistance or drug response by the patients could offer scope to design a customized therapy according to specific characteristics of a particular cancer. Study of cancer in mouse models has gained popularity over the last few decades. Sophisticated genetic manipulation technologies and commercialization of these murine systems have made it possible to generate mice models to study human disease.

Given the large socio-economic burden of cancer, both on academic research and the healthcare industry, there is a need for in vivo animal cancer models that can provide a rationale that is translatable to the clinic. Such a bench-to-bedside transition is likely to facilitate long-term growth of the global mice model generation market. The Mouse Avatar and Co-clinical Trial concepts have the potential to revolutionize the drug development and healthcare process.

High Efficiency and Flexibility to Drive CRISPR Knockout Segment

In terms of technology, the global mice model generation market has been segmented into CRISPR knockout, CRISPR knockin, random insertions, large & targeted insertions, ES cell modification (homologous recombination), and others. The CRISPR knockout segment held dominant share of the market in 2021. The segment is likely to lead the global market during the forecast period by registering the highest CAGR. High efficiency and flexibility of the CRISPR gene editing technology is expected to drive the CRISPR knockout segment during the forecast period. As per the global mice model generation market trends, usage of CRISPR technology for the development of CRISPR knockout mice is likely to increase in the next few years.

Substantial Usage of CRISPR Technology to Fuel Biotechnology Companies Segment

Based on end-user, the global mice model generation market has been classified into pharmaceutical companies, biotechnology companies, academic & research facilities, and contract research & manufacturing organizations. The biotechnology companies segment is projected to account for significant share of the global mice model generation market from 2022 to 2031. The segment is anticipated to exhibit the highest CAGR during the forecast period. High adoption of CRISPR technology by biotechnology companies and research laboratories is driving the segment. For instance, in October 2016, Caribou Biosciences granted The Jackson Laboratory non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes. However, the academic & research facilities segment is expected to register the highest growth rate during the forecast period. Increase in funding for academic research institutes for mice model research is augmenting the segment.

Regional Outlook of Global Mice Model Generation Market

North America dominated the global mice model generation market, with more than 40% share in 2021. Well-established pharmaceutical & biopharmaceutical research industry and presence of some of the world’s leading pharmaceutical and biopharmaceutical companies in the region make it highly promising for various products employed in research activities. This is projected to drive the mice model generation market in North America during the forecast period.

The market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Increase in the usage of mice models for research purposes due to the COVID-19 outbreak is anticipated to drive the market in the region during the forecast period.

Key Developments in Global Mice Model Generation Market

• In July 2022, GemPharmatech announced that it had entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America
• In March 2022, Charles River Laboratories signed an agreement to breed, distribute, market, and sell Hera BioLabs' SRG rat to the global preclinical research community. Unlike other immunodeficient rodent strains, such as the nude rat, the SRG (Sprague Dawley, Rag2, Il2rg-"SRG") is a severely immunodeficient model created through knockout mutations in the Rag2 and Il2r gamma genes that result in mature B, T, and NK cell deficiencies. This severe immunodeficiency, combined with a larger organism size, makes the SRG rat an ideal alternative research model to mice in certain preclinical applications.
• In May 2021, the La Jolla Institute for Immunology (LJI) entered into a partnership agreement with Synbal, Inc. to develop ulti-gene, humanized mouse models for COVID-19 research. The research at LJI is expected to be led by Professor Shresta. By combining Synbal’s proprietary gene-editing platform, Active Genetics, with Shresta’s expertise in characterization of immune responses to emerging and re-emerging viral pathogens, the team plans to develop several humanized mice models to study COVID-19.
• In May 2020, Oragenics, Inc. announced that through its wholly-owned subsidiary, Noachis Terra, it had entered into an agreement with Aragen Bioscience to advance TerraCov2, the company’s SARS CoV-2 vaccine candidate. Under the terms of the agreement, Aragen is likely to provide cell line development services to Oragenics to aid the development of Oragenics’ TerraCoV2, which could provide specific immunity from the novel coronavirus, the root cause of COVID-19.
• In March 2019, Charles River Laboratories inked a licensing deal with drug discovery and development services provider, Crown Bioscience, for an extended access to the Zucker Diabetic Sprague-Dawley (ZDSD) rat model. Under the terms of the deal, Charles River gets an exclusive license to breed and distribute the ZDSD model in the rat model market. In return, Crown Bio is guaranteed a premium-quality and prioritized supply of ZDSD models to support its service platforms.

Some of the prominent players in the Mice Model Generation Market include:

• B BIOCYTOGEN
• Charles River Laboratories
• Cyagen Biosciences
• Gempharmatech
• genOway
• ingenious targeting laboratory
• Ozgene Pty Ltd.
• Taconic Biosciences, Inc.
• PolyGene AG
• THE JACKSON LABORATORY
• Yale School of Medicine
• University of North Carolina
• University of Nebraska Medical Center
• Monash University
• UMass Chan Medical School
• University of Bonn
• Columbia University
• The University of Arizona
• The Weizmann Institute of Science
• The Hebrew University of Jerusalem
• The Technion – Israel Institute of Technology
• Hadassah BrainLabs

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Mice Model Generation market

• Technology
• CRISPR Knockout
• CRISPR Knockin
• Random Insertions
• Large & Targeted Insertions
• ES Cell Modification (homologous recombination)
• Others
• End-user
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Facilities
• Contract Research & Manufacturing Organizations

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Mice Model Generation industry analysis from 2022 to 2030 to identify the prevailing Mice Model Generation industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Mice Model Generation industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Mice Model Generation industry trends, key players, market segments, application areas, and market growth strategies